Should I buy Fortrea (FTRE) stock or is it too late?

Fortrea · Health Care · price $19
Logo FortreaSee the full Fortrea (FTRE) profile
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

Firm-by-firm track record on Fortrea

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Baird20 %-11.0 %5$16 -15%
Barclays0 %-101.1 %5$22 +17%
B of A Securities100 %+63.7 %5
In short — Should you invest in Fortrea? Is it too late, still worth it? Analysts are fairly positive (67% buy, median target $23, i.e. +19%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 67% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
  • Median price target $23, i.e. +19% from the current price ($19).

⚠️ Reasons to hesitate

  • Even the most reliable firm on FTRE, Baird (20% hit rate, 5 scored calls), only targets $16 (call made on February 27, 2026, maturing on February 27, 2027) (-15%) in its most recent call, and $14 (call made on September 3, 2025, maturing on September 3, 2026) (-26%) in the one coming due soonest. The stock may already have run past its target.
  • The consensus is not unanimous: of 6 ratings, 2 are neutral.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on FTRE

Median target $23 (+19%) · 6 ratings · Buy consensus

Strong Buy00%
Buy467%
Hold233%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Fortrea now?

We won't decide for you. The facts: 67% of analysts rate it a buy, median target $23 (+19%), and Baird (most reliable on FTRE, 20%) targets $16. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Fortrea?

Not according to analysts: the median target ($23) is still +19% above the current price ($19) (most reliable on FTRE: Baird, 20%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Fortrea still worth investing in?

It depends on the gap between the price ($19) and its estimated value: analysts target $23 on median (+19%), with 67% buys (most reliable on FTRE: Baird, 20%). Cross-check with their real reliability on FTRE and the cautions above. Information, not advice.

What's the main risk in buying FTRE?

Even the most reliable firm on FTRE, Baird (20% hit rate, 5 scored calls), only targets $16 (call made on February 27, 2026, maturing on February 27, 2027) (-15%) in its most recent call, and $14 (call made on September 3, 2025, maturing on September 3, 2026) (-26%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full Fortrea profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)